Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I/II CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF ADVANCED SOLID TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**"), is pleased to announce that an open-label, multi-centre Phase I/II clinical trial (the "**Clinical Trial**") evaluating the safety, tolerability, pharmacokinetic profile and preliminary efficacy of SYS6043 (B7-H3-ADC) (the "**Product**") developed by the Group, either as monotherapy or in combination with bevacizumab and/or chemotherapy, in participants with advanced solid tumours, has been officially initiated at the first centre in China.

The Product is an antibody-drug conjugate (ADC) targeting B7-H3 developed by the Group. Its antibody moiety can specifically bind to the surface of cells expressing B7-H3 and be internalised into the cells. Its linker-drug comprises a tetrapeptide linker conjugated to a topoisomerase I inhibitor, which can be specifically cleaved by proteases to release the small-molecule toxin to kills tumor cells, and exerts a bystander effect to non-specifically kill surrounding tumor tissue cells. Unlike antibodies utilising traditional wild-type fragment crystallizable (Fc) regions, the Product can reduce lymphocyte uptake and lower the risk of off-target toxicity, thereby improving treatment safety.

Previously, the Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China for the Product in September 2026, and following the approval, initiated the Clinical Trial. The Clinical Trial initiated this time is an open-label, multi-centre Phase I/II clinical trial aiming to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of the Product as a monotherapy or in combination with bevacizumab and/or chemotherapy in participants with advanced solid tumours. Currently, the recruitment and screening of participants for the Clinical Trial are actively underway

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 30 October 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.